The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies

For Immediate ReleaseChicago, IL – July 1, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meta Platforms, Inc. META, ServiceNow, Inc. NOW, Booking Holdings Inc. BKNG, Vaso Corp. VASO and bioAffinity Technologies, Inc. BIAF.Here are highlights from Monday’s Analyst Blog:Top Research Reports for Meta Platforms, ServiceNow and Booking HoldingsThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc., ServiceNow, Inc. and Booking Holdings Inc., as well as two micro-cap stocks Vaso Corp. and bioAffinity Technologies, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Through 1H 2025, U.S. Economy Threads the NeedleToday's Featured Research ReportsMeta Platforms' shares have outperformed the Zacks Internet - Software industry over the year-to-date period (+25.5% vs. +16.3%). The company is benefiting from steady user growth across all regions, particularly Asia Pacific. Increased engagement for its offerings like Instagram, WhatsApp, Messenger and Facebook has been a major growth driver.META has been leveraging AI to improve the potency of its platform offerings. These services currently reach more than 3.43 billion people daily. Meta Platforms' growing footprint among young adults, driven by improving recommendations, boosts its competitive prowess. AI usage is making it a popular name among advertisers. This is expected to drive top-line growth.Meta Platforms now expects to invest significantly more over the next few years in developing advanced models and the largest AI services in the world. However, monetization of these AI services will take considerable time, which is a concern.(You can read the full research report on Meta Platforms here >>>)Shares of ServiceNow have outperformed the Zacks Computers - IT Services industry over the past year (+29.5% vs. +8.5%). The company has been benefiting from the rising adoption of its workflows by enterprises undergoing digital transformation. It had nine deals greater than $5 million in net new annual contract value (ACV).ServiceNow closed 72 deals greater than $1 million net new ACV. Generative Artificial Intelligence (Gen AI) deals continued to gain traction. ServiceNow is extensively leveraging AI and machine learning technologies to boost the potency of its solutions. The number of Pro Plus deals more than quadrupled year-over-year, including 39 deals with three or more Now Assist products.ServiceNow is riding on an expanding partner base and acquisitions. For 2025, ServiceNow raised subscription revenues guidance by $5 million at the mid-point. However, NOW is suffering from stiff competition.(You can read the full research report on ServiceNow here >>>)Booking's shares have outperformed the Zacks Internet - Commerce industry over the year-to-date period (+15% vs. +8%). The company is benefiting from a favorable travel demand environment, owing to the growing demand for global leisure travel demand. Substantial improvement in its booking trends remains a major tailwind.Solid momentum in booked room nights is contributing well to the gross bookings' growth. Strong growth in rental car and airline ticket units is a major positive. Strong momentum across the merchant, and advertising and other businesses are key growth drivers for BKNG. The growing alternative accommodation business and flight capabilities are tailwinds for the company.However, sluggishness in its agency business due to the declining trend in agency bookings is a major headwind. Rising macroeconomic and geopolitical tensions are concerning for the company's prospects.(You can read the full research report on Booking here >>>)Shares of Vaso have outperformed the Zacks Medical - Instruments industry over the year-to-date period (+7.6% vs. -8.9%). This microcap company with a market capitalization of $22.67 million has a diversified revenue model — anchored in IT services, professional sales and MedTech — supports operational stability and growth, with 2024 revenue up 7.1% and continued first-quarter 2025 growth.The IT segment's high recurring revenue and GE HealthCare tie-up drive stability and margin strength. A strong balance sheet with $25.3 million in cash and no debt enables strategic flexibility. Deferred revenue growth to $35.4 million enhances visibility, while fourth-quarter seasonality boosts annual earnings.Yet, margin compression, execution missteps, dependency on GEHC, cost inefficiencies and weak free cash flow raise concerns. SaaS underperformance warrants caution on long-term scalability and profitability. Vaso is undervalued to peers, potentially offering upside if operational execution improves and structural risks are mitigated.(You can read the full research report on Vaso here >>>)bioAffinity Technologies' shares have underperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (-70.3% vs. -2.7%). This microcap company with a market capitalization of $8.42 million has efficiency gains and cost cuts which enhance scalability, but liquidity risk looms, with funding needed beyond August 2025.Revenue remains reliant on CyPath Lung, still marketed as an LDT amid regulatory shifts. Competitive, regulatory and trial execution risks could hinder commercialization. The valuation reflects deep value but demands high conviction in execution.Nevertheless, CyPath Lung's clinically superior, non-invasive lung cancer diagnostic, with 92% sensitivity and 87% specificity, outperforms standard methods. Real-world validation supports the uptake in high-risk patients, while reducing the need for invasive procedures.Commercial momentum is accelerating via FSS, regional expansion and a logistics tie-up, with scalable operations and $3.8 million in annual cost savings. Economic models show $1.27 billion in potential system-wide savings, strengthening payer appeal.(You can read the full research report on bioAffinity Technologies here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                      https://www.zacks.com                                                 Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ServiceNow, Inc. (NOW): Free Stock Analysis Report Vaso Corporation (VASO): Get Free Report Booking Holdings Inc. (BKNG): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report bioAffinity Technologies, Inc. (BIAF): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks